- Open Access
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
Alzheimer's Research & Therapy volume 10, Article number: 99 (2018)
- The original article was published in Alzheimer's Research & Therapy 2017 9:95
Following publication of the original article , the authors reported errors in the formatting of the table. The details of the errors are as follows:
In Table 1, the data presented do not correspond to the row title:
The education row currently contains incorrect data.
The weight row currently contains the years of education.
The APOEε4 genotype row currently contains the weight data.
In Table 1, the data should be displayed as follows:
Intention-to-treat population (n = 797)
(n = 266)
(n = 271)
(n = 260)
Age, years, mean (SD)
Education, years, mean (SD)
Weight, kg, mean (SD)
APOEε4 genotype, %a
Ostrowitzki S, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimer's Research & Therapy. 2017;9:95. https://doi.org/10.1186/s13195-017-0318-y.
About this article
Cite this article
Ostrowitzki, S., Lasser, R.A., Dorflinger, E. et al. Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alz Res Therapy 10, 99 (2018). https://doi.org/10.1186/s13195-018-0409-4